These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 20442512)

  • 21. Transcriptional anti-angiogenesis therapy of human pancreatic cancer.
    Xie K; Wei D; Huang S
    Cytokine Growth Factor Rev; 2006 Jun; 17(3):147-56. PubMed ID: 16516532
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chromosomal instability in pancreatic ductal cells from patients with chronic pancreatitis and pancreatic adenocarcinoma.
    Moskovitz AH; Linford NJ; Brentnall TA; Bronner MP; Storer BE; Potter JD; Bell RH; Rabinovitch PS
    Genes Chromosomes Cancer; 2003 Jun; 37(2):201-6. PubMed ID: 12696069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2: novel chemotherapeutic targets in pancreatic endocrine tumors?
    Bergmann F; Breinig M; Höpfner M; Rieker RJ; Fischer L; Köhler C; Esposito I; Kleeff J; Herpel E; Ehemann V; Friess H; Schirmacher P; Kern MA
    Am J Gastroenterol; 2009 Jan; 104(1):171-81. PubMed ID: 19098866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis.
    Li L; Braiteh FS; Kurzrock R
    Cancer; 2005 Sep; 104(6):1322-31. PubMed ID: 16092118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Homeostatic restoration of desmoplastic stroma rather than its ablation slows pancreatic cancer progression.
    Froeling FE; Kocher HM
    Gastroenterology; 2015 Apr; 148(4):849-50. PubMed ID: 25724458
    [No Abstract]   [Full Text] [Related]  

  • 26. Targeting pancreatic ductal adenocarcinoma: New therapeutic options for the ongoing battle.
    Malhotra P; Palanisamy R; Falasca M
    Hepatobiliary Pancreat Dis Int; 2022 Feb; 21(1):4-6. PubMed ID: 34535394
    [No Abstract]   [Full Text] [Related]  

  • 27. [Present status of drug therapy of pancreatic diseases].
    Nakamura K; Yoshimori M
    Nihon Rinsho; 1980; 38(1):202-4. PubMed ID: 7392211
    [No Abstract]   [Full Text] [Related]  

  • 28. Adjuvant Chemotherapy for Stage I Pancreatic Ductal Adenocarcinoma-Is It Based on Evidence or Clinical Wisdom?
    Gervaso L; Lordick F; Fazio N
    JAMA Oncol; 2021 Dec; 7(12):1759-1760. PubMed ID: 34617958
    [No Abstract]   [Full Text] [Related]  

  • 29. ASO Author Reflections: Preceding Systemic Chemotherapy Might Provide Better Prognosis for Pancreatic Ductal Adenocarcinoma with Positive Peritoneal Cytology.
    Ariake K; Mizuma M; Motoi F; Unno M
    Ann Surg Oncol; 2021 Oct; 28(11):6255-6256. PubMed ID: 33634387
    [No Abstract]   [Full Text] [Related]  

  • 30. Repurposed Drugs in Pancreatic Ductal Adenocarcinoma: An Update.
    Ilmer M; Westphalen CB; Niess H; DʼHaese JG; Angele MK; Werner J; Renz BW
    Cancer J; 2019; 25(2):134-138. PubMed ID: 30896536
    [No Abstract]   [Full Text] [Related]  

  • 31. APX005M, a CD40 monoclonal antibody, for patients with pancreatic adenocarcinoma.
    Reni M
    Lancet Oncol; 2021 Jan; 22(1):10-11. PubMed ID: 33387488
    [No Abstract]   [Full Text] [Related]  

  • 32. Phytoestrogens and antioxidants--bits of experimental evidence.
    Mariani SM
    MedGenMed; 2005 Jan; 7(1):25. PubMed ID: 16369330
    [No Abstract]   [Full Text] [Related]  

  • 33. Metabolic disorder, inflammation, and deregulated molecular pathways converging in pancreatic cancer development: implications for new therapeutic strategies.
    Motoo Y; Shimasaki T; Ishigaki Y; Nakajima H; Kawakami K; Minamoto T
    Cancers (Basel); 2011 Jan; 3(1):446-60. PubMed ID: 24212624
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel combinatorial nanotechnology-based oral chemopreventive regimen demonstrates significant suppression of pancreatic cancer neoplastic lesions.
    Grandhi BK; Thakkar A; Wang J; Prabhu S
    Cancer Prev Res (Phila); 2013 Oct; 6(10):1015-1025. PubMed ID: 24072676
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extracellular DNA in pancreatic cancer promotes cell invasion and metastasis.
    Wen F; Shen A; Choi A; Gerner EW; Shi J
    Cancer Res; 2013 Jul; 73(14):4256-66. PubMed ID: 23722544
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The 'N-factors' in pancreatic cancer: functional relevance of NF-κB, NFAT and Nrf2 in pancreatic cancer.
    Arlt A; Schäfer H; Kalthoff H
    Oncogenesis; 2012 Nov; 1(11):e35. PubMed ID: 23552468
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aberrant glycogen synthase kinase 3β in the development of pancreatic cancer.
    Shimasaki T; Kitano A; Motoo Y; Minamoto T
    J Carcinog; 2012; 11():15. PubMed ID: 23230392
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Arousal of cancer-associated stromal fibroblasts: palladin-activated fibroblasts promote tumor invasion.
    Brentnall TA
    Cell Adh Migr; 2012; 6(6):488-94. PubMed ID: 23076142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pancreatic ductal adenocarcinoma.
    Funamizu N; Hu C; Lacy C; Schetter A; Zhang G; He P; Gaedcke J; Ghadimi MB; Ried T; Yfantis HG; Lee DH; Subleski J; Chan T; Weiss JM; Back TC; Yanaga K; Hanna N; Alexander HR; Maitra A; Hussain SP
    Int J Cancer; 2013 Feb; 132(4):785-94. PubMed ID: 22821831
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inflammation and pancreatic ductal adenocarcinoma: a potential scenario for novel drug targets.
    Uomo I; Miraglia S; Pastorello M
    JOP; 2010 May; 11(3):199-202. PubMed ID: 20442512
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.